1. Home
  2. WOLF vs IMCR Comparison

WOLF vs IMCR Comparison

Compare WOLF & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wolfspeed Inc.

WOLF

Wolfspeed Inc.

N/A

Current Price

$24.87

Market Cap

1.5B

Sector

Technology

ML Signal

N/A

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

N/A

Current Price

$29.92

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WOLF
IMCR
Founded
1987
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2025
2016

Fundamental Metrics

Financial Performance
Metric
WOLF
IMCR
Price
$24.87
$29.92
Analyst Decision
Hold
Buy
Analyst Count
2
12
Target Price
$24.00
★ $59.40
AVG Volume (30 Days)
★ 2.9M
524.6K
Earning Date
11-04-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 30.39
EPS
N/A
★ N/A
Revenue
★ $1,385,982,000.00
$249,428,000.00
Revenue This Year
$14.87
$9.30
Revenue Next Year
$4.07
$10.23
P/E Ratio
N/A
★ N/A
Revenue Growth
19.00
★ 43.05
52 Week Low
$13.49
$27.50
52 Week High
$80.82
$40.71

Technical Indicators

Market Signals
Indicator
WOLF
IMCR
Relative Strength Index (RSI) 49.12 45.65
Support Level $23.31 $27.91
Resistance Level $26.70 $31.11
Average True Range (ATR) 2.31 1.50
MACD 0.49 0.04
Stochastic Oscillator 61.73 39.13

Price Performance

Historical Comparison
WOLF
IMCR

About WOLF Wolfspeed Inc.

Wolfspeed Inc is an innovator of wide bandgap semiconductors, focused on silicon carbide materials and devices for power applications. Its product families include silicon carbide materials and power devices. Its products are targeted for various applications in the Automotive domain, including electric vehicles and fast charging, as well as existing and emerging applications in the Industrial & Energy domain such as AI data centers, grid modernization and renewable energy and storage as well as aerospace and defense. The company also use contract manufacturers, some of which include captive lines, for certain products and aspects of product fabrication, assembly and packaging. The company has one reportable segment. Majority of revenue comes from United States followed by Hong Kong.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: